No biomarker No biomarker	T Acute Lymphoblastic Leukemia T Acute Lymphoblastic Leukemia	nelarabine Sensitive: A1 - Approval
No biomarker No biomarker	T Acute Lymphoblastic Leukemia T Acute Lymphoblastic Leukemia	cyclophosphamide oral + etoposide oral + nelarabine Sensitive: A2 - Guideline
TP53 mutation TP53 mutation	T Acute Lymphoblastic Leukemia T Acute Lymphoblastic Leukemia	venetoclax Sensitive: C1 - Off-label
NOTCH1 mutation NOTCH1 mutation	T Acute Lymphoblastic Leukemia T Acute Lymphoblastic Leukemia	prednisone Sensitive: C3 – Early Trials
FBXW7 mutation FBXW7 mutation	T Acute Lymphoblastic Leukemia T Acute Lymphoblastic Leukemia	prednisone Resistant: C3 – Early Trials
HGF-L HGF-L	T Acute Lymphoblastic Leukemia T Acute Lymphoblastic Leukemia	mogamulizumab Resistant: C3 – Early Trials
NOTCH1 L1574Q NOTCH1 L1574Q	T Acute Lymphoblastic Leukemia T Acute Lymphoblastic Leukemia	prednisone Sensitive: C3 – Early Trials
NOTCH1 V1577E NOTCH1 V1577E	T Acute Lymphoblastic Leukemia T Acute Lymphoblastic Leukemia	prednisone Sensitive: C3 – Early Trials
NOTCH1 L1600Q NOTCH1 L1600Q	T Acute Lymphoblastic Leukemia T Acute Lymphoblastic Leukemia	prednisone Sensitive: C3 – Early Trials
NOTCH1 L1585R NOTCH1 L1585R	T Acute Lymphoblastic Leukemia T Acute Lymphoblastic Leukemia	prednisone Sensitive: C3 – Early Trials
NOTCH1 V1577A NOTCH1 V1577A	T Acute Lymphoblastic Leukemia T Acute Lymphoblastic Leukemia	prednisone Sensitive: C3 – Early Trials
NOTCH1 L1600P NOTCH1 L1600P	T Acute Lymphoblastic Leukemia T Acute Lymphoblastic Leukemia	prednisone Sensitive: C3 – Early Trials
NOTCH1 L1574P NOTCH1 L1574P	T Acute Lymphoblastic Leukemia T Acute Lymphoblastic Leukemia	prednisone Sensitive: C3 – Early Trials
NOTCH1 F1592S NOTCH1 F1592S	T Acute Lymphoblastic Leukemia T Acute Lymphoblastic Leukemia	prednisone Sensitive: C3 – Early Trials
NOTCH1 F1592C NOTCH1 F1592C	T Acute Lymphoblastic Leukemia T Acute Lymphoblastic Leukemia	prednisone Sensitive: C3 – Early Trials
JAK3 mutation JAK3 mutation	T Acute Lymphoblastic Leukemia T Acute Lymphoblastic Leukemia	tofacitinib Resistant: C4 – Case Studies
SET-NUP214 fusion + CAN-NUP214 fusion SET-NUP214 fusion + CAN-NUP214 fusion	T Acute Lymphoblastic Leukemia T Acute Lymphoblastic Leukemia	ADE Sensitive: C4 – Case Studies
MEF2C overexpression MEF2C overexpression	T Acute Lymphoblastic Leukemia T Acute Lymphoblastic Leukemia	ABT-737 Sensitive: D – Preclinical
PAK2 overexpression PAK2 overexpression	T Acute Lymphoblastic Leukemia T Acute Lymphoblastic Leukemia	FRAX597 + PF-3758309 Sensitive: D – Preclinical
MCL1 underexpression MCL1 underexpression	T Acute Lymphoblastic Leukemia T Acute Lymphoblastic Leukemia	venetoclax + BI 6727 Sensitive: D – Preclinical
MYC underexpression MYC underexpression	T Acute Lymphoblastic Leukemia T Acute Lymphoblastic Leukemia	venetoclax + BI 6727 Sensitive: D – Preclinical
CCND3 deletion CCND3 deletion	T Acute Lymphoblastic Leukemia T Acute Lymphoblastic Leukemia	palbociclib Sensitive: D – Preclinical
JAK3 M511I JAK3 M511I	T Acute Lymphoblastic Leukemia T Acute Lymphoblastic Leukemia	tofacitinib XR Sensitive: D – Preclinical
JAK3 M511I JAK3 M511I	T Acute Lymphoblastic Leukemia T Acute Lymphoblastic Leukemia	ruxolitinib Sensitive: D – Preclinical
NOTCH1 mutation NOTCH1 mutation	T Acute Lymphoblastic Leukemia T Acute Lymphoblastic Leukemia	CB-839 Sensitive: D – Preclinical
NOTCH1 mutation NOTCH1 mutation	T Acute Lymphoblastic Leukemia T Acute Lymphoblastic Leukemia	IACS-010759 Sensitive: D – Preclinical
BCL2L1 underexpression BCL2L1 underexpression	T Acute Lymphoblastic Leukemia T Acute Lymphoblastic Leukemia	venetoclax + BI 6727 Sensitive: D – Preclinical
PRC2 mutation PRC2 mutation	T Acute Lymphoblastic Leukemia T Acute Lymphoblastic Leukemia	JQ-1 Sensitive: D – Preclinical
PCDHB15 overexpression PCDHB15 overexpression	T Acute Lymphoblastic Leukemia T Acute Lymphoblastic Leukemia	ruxolitinib Sensitive: D – Preclinical
NUP214-ABL1 rearrangement NUP214-ABL1 rearrangement	T Acute Lymphoblastic Leukemia T Acute Lymphoblastic Leukemia	dasatinib Sensitive: D – Preclinical
TCRB-LCK translocation TCRB-LCK translocation	T Acute Lymphoblastic Leukemia T Acute Lymphoblastic Leukemia	dasatinib Sensitive: D – Preclinical
RPL10 R98S RPL10 R98S	T Acute Lymphoblastic Leukemia T Acute Lymphoblastic Leukemia	venetoclax Sensitive: D – Preclinical
NT5C2 R367Q NT5C2 R367Q	T Acute Lymphoblastic Leukemia T Acute Lymphoblastic Leukemia	mercaptopurine Resistant: D – Preclinical

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

T Acute Lymphoblastic Leukemia

Associations(33)

Associations
(33)